Patients with advanced estrogen receptor (ER)-positive breast cancer that progressed on CDK4/6 inhibitors had better survival ...

Targeting the estrogen receptor and HER2 pathways improved progression-free survival in patients with HR-positive, ...

New DESTINY-Breast06 analysis showed trastuzumab deruxtecan doubled PFS versus chemotherapy in patients with rapid ...

The model uses clinical and genomic features to predict whether patients will respond to first-line CDK4/6 and endocrine therapy.

Seven in vitro studies evaluate the “effects of pesticides on the anatomy and physiology of hepatocytes and adipocytes” and ...

The CDK4/6 inhibitor palbociclib (Ibrance; Pfizer) led to a significant improvement in progression-free survival (PFS) in patients with HR-positive, HER2-positive metastatic breast cancer when added ...

Abnormalities in endocrine functions have been reported in stroke ... However, another limitation of dosing copeptin in ischemic stroke patients is that this biomarker can be significantly higher in ...

Results of the a phase III clinical trial called EMBER-3 indicate the promise and efficacy of a drug called imlunestrant. This is a new kind of oral selective estrogen receptor degrader (SERD), used ...

Various biomarkers, including T-cell inflamed 18-gene expression profile, were positively prognostic for improved pathologic complete response (pCR) and event-free survival (EFS), with or without the ...

The aim of this Research Topic was to accelerate pioneering research and deepen our understanding of endocrine-related cancers. By spotlighting groundbreaking studies on targeted therapies, biomarker ...